» Articles » PMID: 35327496

Vascular Analysis of Type 1, 2, and 3 Macular Neovascularization in Age-Related Macular Degeneration Using Swept-Source Optical Coherence Tomography Angiography Shows New Insights into Differences of Pathologic Vasculature and May Lead to a More...

Overview
Journal Biomedicines
Date 2022 Mar 25
PMID 35327496
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The clinical appearance of macular neovascularization (MNV) in age-related macular degeneration (nAMD) varies widely, but so far, this has had no relevance in terms of therapeutic approaches or prognosis. Therefore, our purpose was to investigate if and which differences exist in the vascular architecture of MNV and to quantify them. Methods: In 90 patients with newly diagnosed nAMD, MNV was identified by means of optical coherence tomography angiography (OCTA), and automated quantitative vascular analysis was carried out. The analyzed vascular parameters were area, flow, fractal dimension (FD), total vascular length (sumL), number of vascular nodes (numN), flow, and average vessel caliber (avgW). The current classification of MNVs divides them according to their localization into type 1 (grown from the choroid below the RPE), type 2 (grown from the choroid through RPE), and type 3 (grown from the retina toward the RPE). We compared the analyzed vascular parameters of each of the three MNV types. Kruskal−Wallis test was applied, Dunn test was performed for post hoc analysis, and for pairwise comparison, p-values were adjusted using Bonferroni comparison. Results: Regarding the MNV area, there was no significant difference between types 1 and 2, but type 3 was significantly smaller than types 1 and 2 (p < 0.00001). For FD, types 1 and 2 did not differ significantly, but again, type 3 was lower than type 1 and 2 (p < 0.00001). The numN were significantly higher in types 1 and 3 than in 2 (p < 0.005), but not between types 1 and 3. No significant differences were found between MNV types for flow. As for sumL, types 1 and 2 did not differ significantly, but type 3 was significantly lower than types 1 and 2 (p < 0.00001). For avgW, there was no significant difference between types 1 and 2 or between types 2 and 3, but type 3 was significantly larger than type 1 (p < 0.05). Conclusions OCTA yields detailed information on the vascular morphology of MNV in patients with nAMD and is able to show differences among types 1, 2, and 3. Especially comparing types 1 and 2 with type 3 reveals significant differences in area, FD, sumL, and numN. One explanation could be the similar pathogenesis of types 1 and 2 with their origin in the choroid and their growth towards the retinal pigment epithelium (RPE), whereas type 3 originates in the deep capillary plexus. Between types 1 and 2, however, only the numN differ significantly, which could be due to the fact that type 1 spreads horizontally below the RPE and, thus, display more vascular branching, while type 2 grows more vertically through the RPE and under the neurosensory retina. Detailed information about the pathologic vasculature is important for proper monitoring of the disease and to assess the efficacy of medication, especially with regard to new substances. This should be taken into consideration in future studies.

Citing Articles

Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration.

Honda S, Maruyama-Inoue M, Otsuji T, Kyo A, Kobayashi Y, Yamamoto Y Sci Rep. 2025; 15(1):5705.

PMID: 39962248 PMC: 11833093. DOI: 10.1038/s41598-025-89638-1.


Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab.

Rossi S, Gesualdo C, Marano E, Perrotta R, Trotta M, Del Giudice A Front Med (Lausanne). 2025; 11:1467160.

PMID: 39886454 PMC: 11780245. DOI: 10.3389/fmed.2024.1467160.


Overview of the Use of Optical Coherence Tomography Angiography in Neovascular Age-Related Macular Degeneration.

Faatz H, Lommatzsch A J Clin Med. 2024; 13(17).

PMID: 39274255 PMC: 11396513. DOI: 10.3390/jcm13175042.


Developing quantitative analysis program of blood flow velocity according to vessel diameter for neovascular age-related macular degeneration using OCTA-VISTA.

Tanaka F, Mino T, Moriguchi Y, Nagahama H, Tamura M, Oshima Y Sci Rep. 2024; 14(1):16352.

PMID: 39013988 PMC: 11252384. DOI: 10.1038/s41598-024-67271-8.


Dynamics and patterns of recurrence in neovascular AMD during real-world management using automated fluid monitoring.

Prenner V, Schmidt-Erfurth U, Fuchs P, Leingang O, Coulibaly L, Bogunovic H Heliyon. 2024; 10(10):e31567.

PMID: 38826751 PMC: 11141345. DOI: 10.1016/j.heliyon.2024.e31567.


References
1.
Fleckenstein M, Keenan T, Guymer R, Chakravarthy U, Schmitz-Valckenberg S, Klaver C . Age-related macular degeneration. Nat Rev Dis Primers. 2021; 7(1):31. DOI: 10.1038/s41572-021-00265-2. View

2.
Kim K, You J, Park J, Kim E, Oh W, Yu S . Quantification of retinal microvascular parameters by severity of diabetic retinopathy using wide-field swept-source optical coherence tomography angiography. Graefes Arch Clin Exp Ophthalmol. 2021; 259(8):2103-2111. DOI: 10.1007/s00417-021-05099-y. View

3.
Arrigo A, Romano F, Aragona E, Di Nunzio C, Battista M, Bandello F . OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CAN CATEGORIZE DIFFERENT SUBGROUPS OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. 2020; 40(12):2263-2269. DOI: 10.1097/IAE.0000000000002775. View

4.
Pauleikhoff D, Gunnemann F, Book M, Rothaus K . Progression of vascular changes in macular telangiectasia type 2: comparison between SD-OCT and OCT angiography. Graefes Arch Clin Exp Ophthalmol. 2019; 257(7):1381-1392. DOI: 10.1007/s00417-019-04323-0. View

5.
Faatz H, Farecki M, Rothaus K, Gunnemann F, Gutfleisch M, Lommatzsch A . Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative method. Eye (Lond). 2019; 33(9):1466-1471. PMC: 7002694. DOI: 10.1038/s41433-019-0429-8. View